false12-312021Q2000176430100-0000000P10DP30DP30DP30DP60DP60D0.500017643012021-01-012021-06-300001764301scpe:PublicSharesMember2021-01-012021-06-300001764301us-gaap:CommonClassAMember2021-01-012021-06-300001764301scpe:RedeemableWarrantsMember2021-01-012021-06-300001764301us-gaap:CommonClassBMember2021-08-100001764301us-gaap:CommonClassAMember2021-08-1000017643012020-12-3100017643012021-06-300001764301us-gaap:WarrantMember2021-06-300001764301us-gaap:ForwardContractsMember2021-06-300001764301us-gaap:ForwardContractsMember2020-12-310001764301us-gaap:WarrantMember2020-12-310001764301us-gaap:CommonClassBMember2020-12-310001764301us-gaap:CommonClassBMember2021-06-300001764301us-gaap:CommonClassAMember2020-12-310001764301us-gaap:CommonClassAMember2021-06-3000017643012021-04-012021-06-3000017643012020-04-012020-06-3000017643012020-01-012020-06-300001764301us-gaap:ForwardContractsMember2021-01-012021-06-300001764301us-gaap:WarrantMember2021-01-012021-06-300001764301us-gaap:WarrantMember2020-04-012020-06-300001764301us-gaap:ForwardContractsMember2021-04-012021-06-300001764301us-gaap:ForwardContractsMember2020-04-012020-06-300001764301us-gaap:WarrantMember2020-01-012020-06-300001764301us-gaap:ForwardContractsMember2020-01-012020-06-300001764301us-gaap:WarrantMember2021-04-012021-06-300001764301us-gaap:CommonClassAMember2020-04-012020-06-300001764301us-gaap:CommonClassBMember2020-01-012020-06-300001764301us-gaap:CommonClassBMember2021-04-012021-06-300001764301us-gaap:CommonClassBMember2020-04-012020-06-300001764301us-gaap:CommonClassAMember2020-01-012020-06-300001764301us-gaap:CommonClassAMember2021-04-012021-06-300001764301us-gaap:CommonClassBMember2021-01-012021-06-300001764301us-gaap:AdditionalPaidInCapitalMember2020-12-310001764301us-gaap:CommonStockMemberus-gaap:CommonClassAMember2020-12-310001764301us-gaap:CommonStockMemberus-gaap:CommonClassBMember2019-12-310001764301us-gaap:CommonClassAMemberus-gaap:CommonStockMember2019-12-3100017643012019-12-310001764301us-gaap:AdditionalPaidInCapitalMember2019-12-310001764301us-gaap:RetainedEarningsMember2019-12-310001764301us-gaap:RetainedEarningsMember2020-12-310001764301us-gaap:CommonClassBMemberus-gaap:CommonStockMember2020-12-310001764301us-gaap:CommonStockMemberus-gaap:CommonClassAMember2020-04-012020-06-300001764301us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-3100017643012020-01-012020-03-310001764301us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300001764301us-gaap:CommonClassAMemberus-gaap:CommonStockMember2020-01-012020-03-310001764301us-gaap:RetainedEarningsMember2021-04-012021-06-300001764301us-gaap:CommonStockMemberus-gaap:CommonClassAMember2021-01-012021-03-310001764301us-gaap:RetainedEarningsMember2021-01-012021-03-310001764301us-gaap:RetainedEarningsMember2020-01-012020-03-310001764301us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001764301us-gaap:RetainedEarningsMember2020-04-012020-06-300001764301us-gaap:CommonClassAMemberus-gaap:CommonStockMember2021-04-012021-06-3000017643012021-01-012021-03-310001764301us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001764301us-gaap:CommonStockMemberus-gaap:CommonClassBMember2021-04-012021-06-300001764301us-gaap:CommonStockMemberus-gaap:CommonClassBMember2021-01-012021-03-310001764301us-gaap:CommonClassBMemberus-gaap:CommonStockMember2020-01-012020-03-310001764301us-gaap:CommonClassBMemberus-gaap:CommonStockMember2020-04-012020-06-300001764301us-gaap:RetainedEarningsMember2020-06-300001764301us-gaap:CommonStockMemberus-gaap:CommonClassAMember2020-06-300001764301us-gaap:CommonStockMemberus-gaap:CommonClassBMember2021-03-310001764301us-gaap:RetainedEarningsMember2020-03-310001764301us-gaap:RetainedEarningsMember2021-06-300001764301us-gaap:AdditionalPaidInCapitalMember2021-06-3000017643012020-03-310001764301us-gaap:RetainedEarningsMember2021-03-310001764301us-gaap:CommonClassAMemberus-gaap:CommonStockMember2020-03-310001764301us-gaap:AdditionalPaidInCapitalMember2020-06-3000017643012021-03-310001764301us-gaap:AdditionalPaidInCapitalMember2020-03-3100017643012020-06-300001764301us-gaap:CommonClassBMemberus-gaap:CommonStockMember2020-06-300001764301us-gaap:AdditionalPaidInCapitalMember2021-03-310001764301us-gaap:CommonStockMemberus-gaap:CommonClassBMember2021-06-300001764301us-gaap:CommonStockMemberus-gaap:CommonClassAMember2021-06-300001764301us-gaap:CommonClassAMemberus-gaap:CommonStockMember2021-03-310001764301us-gaap:CommonStockMemberus-gaap:CommonClassBMember2020-03-310001764301us-gaap:CommonClassAMember2021-04-162021-04-160001764301scpe:PublicSharesMemberus-gaap:OverAllotmentOptionMember2019-08-022019-08-020001764301us-gaap:IPOMemberscpe:PublicSharesMember2019-07-162019-07-160001764301scpe:PrivatePlacementWarrantMember2019-07-162019-07-160001764301scpe:PrivatePlacementWarrantMember2019-08-022019-08-020001764301scpe:PrivatePlacementWarrantMember2019-07-160001764301us-gaap:OverAllotmentOptionMemberscpe:PublicSharesMember2019-08-020001764301scpe:PrivatePlacementWarrantMember2019-08-020001764301us-gaap:OverAllotmentOptionMemberscpe:PrivatePlacementWarrantMember2019-08-022019-08-0200017643012019-08-022019-08-020001764301srt:MaximumMember2021-06-300001764301us-gaap:IPOMemberscpe:PublicSharesMember2019-07-1600017643012019-08-020001764301srt:MinimumMember2021-01-012021-06-300001764301scpe:PublicSharesMemberus-gaap:IPOMember2019-08-020001764301srt:MinimumMember2021-06-300001764301us-gaap:OverAllotmentOptionMember2019-08-022019-08-020001764301us-gaap:IPOMember2019-08-022019-08-020001764301us-gaap:IPOMember2019-08-020001764301us-gaap:OverAllotmentOptionMember2019-08-020001764301scpe:RedeemableWarrantsMemberus-gaap:IPOMember2019-08-020001764301us-gaap:CommonClassAMemberus-gaap:IPOMember2019-08-020001764301us-gaap:CommonClassBMemberus-gaap:InvestorMember2019-07-092019-07-090001764301us-gaap:CommonClassBMemberus-gaap:InvestorMember2018-12-012018-12-310001764301us-gaap:InvestorMemberus-gaap:CommonClassBMember2019-02-082019-02-080001764301us-gaap:CommonClassBMemberus-gaap:InvestorMember2019-07-090001764301us-gaap:InvestorMemberus-gaap:CommonClassBMember2019-02-080001764301us-gaap:InvestorMemberus-gaap:CommonClassBMember2021-01-012021-06-300001764301srt:MinimumMemberus-gaap:CommonClassAMemberus-gaap:InvestorMember2021-06-300001764301us-gaap:CommonClassAMemberus-gaap:InvestorMember2021-01-012021-06-300001764301srt:MinimumMemberus-gaap:InvestorMemberus-gaap:CommonClassAMember2021-01-012021-06-300001764301scpe:PrivatePlacementWarrantMemberus-gaap:InvestorMember2019-07-162019-07-160001764301scpe:PrivatePlacementWarrantMemberus-gaap:InvestorMember2019-07-160001764301scpe:PrivatePlacementWarrantMemberus-gaap:IPOMember2019-07-160001764301scpe:PrivatePlacementWarrantMemberus-gaap:CommonClassAMember2021-06-300001764301scpe:AdministrativeSupportAgreementMemberus-gaap:InvestorMember2019-07-162019-07-160001764301us-gaap:InvestorMemberscpe:AdministrativeSupportAgreementMember2021-04-012021-06-300001764301us-gaap:InvestorMemberscpe:AdministrativeSupportAgreementMember2021-01-012021-06-300001764301us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:InvestorMemberscpe:AdministrativeSupportAgreementMember2020-12-310001764301scpe:AdministrativeSupportAgreementMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:InvestorMember2021-06-300001764301us-gaap:InvestorMember2018-12-310001764301us-gaap:InvestorMemberscpe:PromissoryNoteToCoverExpensesRelatedToInitialPublicOfferingMember2019-01-012019-01-310001764301scpe:PromissoryNoteToCoverExpensesRelatedToInitialBusinessCombinationMemberus-gaap:InvestorMember2021-05-252021-05-250001764301us-gaap:InvestorMemberscpe:PromissoryNoteToCoverExpensesRelatedToInitialPublicOfferingMember2018-12-310001764301scpe:PromissoryNoteToCoverExpensesRelatedToInitialPublicOfferingMemberus-gaap:InvestorMember2019-01-012019-12-310001764301scpe:PromissoryNoteToCoverExpensesRelatedToInitialPublicOfferingMemberus-gaap:InvestorMember2021-03-222021-03-220001764301us-gaap:InvestorMemberscpe:PromissoryNoteToCoverExpensesRelatedToInitialPublicOfferingMember2021-04-282021-04-280001764301us-gaap:InvestorMemberscpe:PromissoryNoteToCoverExpensesRelatedToInitialPublicOfferingMember2021-03-312021-03-310001764301scpe:PromissoryNoteToCoverExpensesRelatedToInitialPublicOfferingMemberus-gaap:InvestorMember2020-12-312020-12-310001764301scpe:PromissoryNoteToCoverExpensesRelatedToInitialPublicOfferingMemberus-gaap:InvestorMember2021-06-300001764301us-gaap:InvestorMemberscpe:WorkingCapitalLoansMember2021-01-012021-06-300001764301scpe:WorkingCapitalLoansMemberus-gaap:InvestorMember2021-06-300001764301scpe:WorkingCapitalLoansMemberus-gaap:InvestorMember2020-12-310001764301us-gaap:OverAllotmentOptionMember2021-01-012021-06-300001764301us-gaap:CommonClassAMember2019-07-0900017643012019-07-090001764301scpe:RockleyPhotonicsHoldingsLimitedMember2019-07-090001764301us-gaap:InvestorMember2019-07-092019-07-090001764301us-gaap:ForwardContractsMember2021-01-012021-03-310001764301us-gaap:CommonClassAMember2021-03-190001764301scpe:HoldCoMember2021-03-190001764301scpe:InvestorSubscriptionAgreementsMember2021-03-190001764301scpe:RedeemableWarrantsMember2021-06-300001764301scpe:PrivatePlacementWarrantMember2021-06-300001764301us-gaap:CommonClassAMemberscpe:WarrantsAndRightsSubjectToMandatoryRedemptionOneMember2021-06-300001764301scpe:WarrantsAndRightsSubjectToMandatoryRedemptionOneMemberus-gaap:CommonClassAMember2021-01-012021-06-300001764301us-gaap:CommonClassAMemberscpe:WarrantsAndRightsSubjectToMandatoryRedemptionTwoMember2021-01-012021-06-300001764301us-gaap:CommonClassAMembersrt:MinimumMemberscpe:WarrantsAndRightsSubjectToMandatoryRedemptionOneMember2021-06-300001764301srt:MinimumMemberscpe:WarrantsAndRightsSubjectToMandatoryRedemptionTwoMemberus-gaap:CommonClassAMember2021-06-300001764301scpe:PrivatePlacementWarrantMember2021-01-012021-06-300001764301us-gaap:CommonClassAMembersrt:MinimumMember2021-01-012021-06-300001764301scpe:PrivatePlacementWarrantsMember2020-12-310001764301scpe:PrivatePlacementWarrantsMember2021-06-300001764301us-gaap:CommonClassAMemberus-gaap:ForwardContractsMember2020-12-310001764301us-gaap:ForwardContractsMemberus-gaap:CommonClassAMember2021-06-300001764301scpe:RedeemableWarrantsMember2020-12-310001764301scpe:RedeemableWarrantsMember2021-06-300001764301us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2021-06-300001764301us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2020-12-310001764301us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberscpe:RedeemableWarrantsMember2020-12-310001764301scpe:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001764301us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberscpe:RedeemableWarrantsMember2021-06-300001764301us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberscpe:PrivatePlacementWarrantsMember2020-12-310001764301us-gaap:FairValueInputsLevel3Memberus-gaap:ForwardContractsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001764301us-gaap:ForwardContractsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001764301us-gaap:MeasurementInputExercisePriceMemberscpe:PrivatePlacementWarrantsMember2020-12-310001764301us-gaap:MeasurementInputRiskFreeInterestRateMemberscpe:PrivatePlacementWarrantsMember2021-06-300001764301scpe:PrivatePlacementWarrantsMemberus-gaap:MeasurementInputExercisePriceMember2021-06-300001764301scpe:PrivatePlacementWarrantsMemberus-gaap:MeasurementInputSharePriceMember2020-12-310001764301scpe:PrivatePlacementWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2021-06-300001764301us-gaap:MeasurementInputPriceVolatilityMemberscpe:PrivatePlacementWarrantsMember2020-12-310001764301us-gaap:MeasurementInputRiskFreeInterestRateMemberscpe:PrivatePlacementWarrantsMember2020-12-310001764301us-gaap:MeasurementInputSharePriceMemberscpe:PrivatePlacementWarrantsMember2021-06-300001764301scpe:PrivatePlacementWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2020-01-012020-12-310001764301us-gaap:MeasurementInputExpectedTermMemberscpe:PrivatePlacementWarrantsMember2021-01-012021-06-300001764301us-gaap:ForwardContractsMember2020-12-310001764301us-gaap:ForwardContractsMember2021-04-012021-06-300001764301scpe:PrivatePlacementWarrantsMember2021-01-012021-03-310001764301scpe:PrivatePlacementWarrantsMember2021-04-012021-06-300001764301us-gaap:ForwardContractsMember2021-01-012021-03-310001764301us-gaap:ForwardContractsMember2021-06-300001764301us-gaap:ForwardContractsMember2021-03-310001764301scpe:PrivatePlacementWarrantsMember2021-03-31xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesscpe:Businessxbrli:purescpe:Demandscpe:Vote

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(MARK ONE)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarter ended ~~March~~June 3130, 2021

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from_____________to____________

Commission file number: 001-38972

SC Health Corporation

(Exact Name of Registrant as Specified in Its Charter)

Cayman Islands		N/A
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

108 Robinson Road #10-00 Singapore 068900		068900
108 Robinson Road #10-00, Singapore Singapore 068900		068900
(Address of principal executive offices)		(Zip Code)

+65 6438 1080

(Issuer’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Units, each consisting of one Class A ordinary share, $0.0001 par value, and one half of one warrant	SCPE.U	New York Stock Exchange LLC
Class A ordinary shares, par value $0.0001 per share	SCPE	New York Stock Exchange LLC
Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share	SCPE WS	New York Stock Exchange LLC

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒ No ☐

As of ~~April~~August 3010, 2021, there were 17 9,~~250~~274,~~000~~515 Class A ordinary shares, $0.0001 par value and 5,562,500 Class B ordinary shares, $0.00008 par value, issued and outstanding.

SC HEALTH CORPORATION

FORM 10-Q FOR THE QUARTER ENDED ~~MARCH~~JUNE 3130, 2021

TABLE OF CONTENTS

			Page
Part I. Financial Information
	Item 1. Financial Statements
		Condensed Balance Sheets as of March 31, 2021 and December 31, 2020	1
		Condensed Balance Sheets as of June 30, 2021 (Unaudited) and December 31, 2020	1
		Condensed Interim Statements of Operations for the three months ended March 31, 2021 and 2020 (Unaudited)	2
		Unaudited Condensed Interim Statements of Operations for the three and six months ended June 30, 2021 and 2020	2
		Condensed Statements of Changes in Shareholders’ Equity for the three months ended March 31, 2021 and 2020 (Unaudited)	3
		Unaudited Condensed Statements of Changes in Shareholders’ Equity for the three and six months ended June 30, 2021 and 2020	3
		Condensed Statements of Cash Flows for the three months ended March 31, 2021 and 2020 (Unaudited)	4
		Unaudited Condensed Statements of Cash Flows for the six months ended June 30, 2021 and 2020	4
		Notes to Condensed Interim Financial Statements (Unaudited)	5
	Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		18
	Item 3. Quantitative and Qualitative Disclosures About Market Risk		21
	Item 4. Controls and Procedures		21
Part II. Other Information
	Item 1. Legal Proceedings		22
	Item 1A. Risk Factors		22
	Item 2. Unregistered Sales of Equity Securities and Use of Proceeds from Registered Securities		22
	Item 3. Defaults Upon Senior Securities		23
	Item 4. Mine Safety Disclosures		23
	Item 5. Other Information		23
	Item 6. Exhibits		23
Part III. Signatures			24

Table of Contents

Part I. Financial Information

Item 1.

Financial Statements

SC HEALTH CORPORATION

CONDENSED BALANCE SHEETS

	March 31, 2021			December 31, 2020
	June 30, 2021			December 31, 2020
	(Unaudited)
ASSETS
Current Assets
Cash	$	1035,~~181~~244		$	124,878
Prepaid expenses		~~124~~47,~~215~~876			122,067
Total Current Assets		~~134~~83,~~396~~120			246,945
Marketable securities held in Trust Account		~~174~~93,~~547~~838,~~492~~960			174,542,012
TOTAL ASSETS	$	~~174~~93,~~681~~922,~~888~~080		$	174,788,957
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities
Account payable and accrued expenses	$	1,~~104~~004,~~041~~661		$	1,037,048
Accrued offering costs		167			167
Promissory note – related party		~~185~~1,035,000			100,000
Total Current Liabilities		12,~~289~~039,~~208~~828			1,137,215
Warrant liabilities		3332,~~301~~502,~~342~~932			19,055,750
Forward purchase agreement liabilities		—			2,950,567
Deferred underwriting fee payable		6,037,500			6,037,500
Total Liabilities		40,~~628~~580,~~050~~260			29,181,032
Commitments and Contingencies (Note 5)
Class A ordinary shares subject to possible redemption, 12,905,383 and 14,060,762 shares at $10.00 per share as of March 31, 2021 and December 31, 2020, respectively		129,053,831			140,607,920
Class A ordinary shares subject to possible redemption, 4,834,181 and 14,060,762 shares at $10.00 per share as of June 30, 2021 and December 31, 2020, respectively		48,341,810			140,607,920
Shareholders’ Equity
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding		—			—
Class A ordinary shares, $0.0001 par value; 180,000,000 shares authorized; 4,344,617 and 3,189,208 shares issued and outstanding (excluding 12,905,383 and 14,060,762 shares subject to possible redemption) as of March 31, 2021 and December 31, 2020, respectively		434			319
Class A ordinary shares, $0.0001 par value; 180,000,000 shares authorized; 4,440,334 and 3,189,208 shares issued and outstanding (excluding 4,834,181 and 14,060,762 shares subject to possible redemption) as of June 30, 2021 and December 31, 2020, respectively		444			319
Class B ordinary shares, $0.00008 par value; 25,000,000 shares authorized; 5,562,500 shares issued and outstanding as of March 31, 2021 and December 31, 2020		445			445
Class B ordinary shares, $0.00008 par value; 25,000,000 shares authorized; 5,562,500 shares issued and outstanding as of June 30, 2021 and December 31, 2020		445			445
Additional paid-in capital		30,381,~~491~~594			18,827,517
(Accumulated deficit) Retained earnings		(25,382,363	)		(13,828,276	)
Accumulated deficit		(25,382,473	)		(13,828,276	)
Total Shareholders’ Equity		5,000,~~007~~010			5,000,005
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	~~174~~93,~~681~~922,~~888~~080		$	174,788,957

The accompanying notes are an integral part of these unaudited condensed interim financial statements.

Table of Contents

SC HEALTH CORPORATION

CONDENSED INTERIM STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months Ended March 31,
	Three Months Ended June 30,						Six Months Ended June 30,
	2021			2020			2021			2020
Operating costs	$	264,542		$	212,283
General and operating expenses	$	801,896		$	136,354		$	1,066,438		$	348,637
Loss from operations		(~~264~~801,~~542~~896)	)		(~~212~~136,~~283~~354)	)		(1,066,438)	)		(348,637)	)
Other income:
Other income (expense):
Interest earned on investments held in Trust Account		53,~~480~~376			~~557~~70,~~639~~520			8,856			628,159
Change in fair value of warrant liabilities		~~(14~~798,~~245,592~~410	)		54(1,743,500)	)		(13,447,182)	)		(1,689,000)	)
Change in fair value of forward purchase agreement		~~2,950,567~~—			(~~160~~451,~~098~~927)	)		2,950,567			(612,025)	)
Net Income (Loss)	$	(11,554,087	)	$	239,758
Other income (expense), net		801,786			(2,124,907)	)		(10,487,759)	)		(1,672,866)	)
Weighted average shares outstanding of Class A redeemable ordinary shares		17,250,000			17,250,000
Net loss	$	(110)	)	$	(2,261,261)	)	$	(11,554,197)	)	$	(2,021,503)	)
Basic and diluted net income (loss) per share, Class A	$	0.00		$	0.03
Weighted average shares outstanding of Class A redeemable ordinary shares		10,501,513			17,250,000			13,857,114			17,250,000
Weighted average shares outstanding of Class B non-redeemable ordinary shares		5,562,500			5,562,500
Basic and diluted net income per share, Class A	$	0.00		$	0.00		$	0.00		$	0.04
Basic and diluted net income (loss) per share, Class B	$	(2.08	)	$	(0.06	)
Weighted average shares outstanding of Class B non-redeemable ordinary shares		5,562,500			5,562,500			5,562,500			5,562,500
Basic and diluted net loss per share, Class B	$	(0.00	)	$	(0.42)	)	$	(2.08)	)	$	(0.48)	)

The accompanying notes are an integral part of these unaudited condensed interim financial statements.

Table of Contents

SC HEALTH CORPORATION

CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

(Unaudited)

THREE AND SIX MONTHS ENDED ~~MARCH~~JUNE 3130, 2021

	Class A Ordinary Shares					Class B Ordinary Shares				Additional Paid-in Capital		(Accumulated Deficit~~) Retained Earnings~~			Total Shareholders’ Equity
	Shares			Amount		Shares		Amount
Balance – January 1, 2021		3,189,208		$	319		5,562,500	$	445	$	18,827,517	$	(13,828,276	)	$	5,000,005
Change in value of ordinary shares subject to possible redemption		(1,155,409	)		115		—		—		11,553,974		—			11,554,089
Net income (loss)		—			—		—		—		—		(11,554,087	)		(11,554,087	)
Net loss		—			—		—		—		—		(11,554,087	)		(11,554,087	)
Balance – March 31, 2021 (unaudited)		4,344,617		$	434		5,562,500	$	445	$	30,381,491	$	(25,382,363	)	$	5,000,007
Change in value of ordinary shares subject to possible redemption(1)		95,717			10		—		—		103		—			113
Net income		—			—		—		—		—		(110	)		(110	)
Balance – June 30, 2021 (unaudited)		4,440,334		$	444		5,562,500	$	445	$	30,381,594	$	(25,382,473	)	$	5,000,010

THREE AND SIX MONTHS ENDED ~~MARCH~~JUNE 3130, 2020

	Class A Ordinary Shares						Class B Ordinary Shares				Additional Paid in Capital			(Accumulated Deficit~~) Retained Earnings~~			Total Shareholders’ Equity
	Shares			Amount			Shares		Amount
Balance – January 1, 2020		2,366,966		$	237			5,562,500	$	445	$	10,605,179		$	(5,605,856	)	$	5,000,005
Change in value of ordinary shares subject to possible redemption		(23,976	)		(3	)		—		—		(239,757	)		—			(239,760	)
Net income		—			—			—		—		—			239,758			239,758
Balance – March 31, 2020 (unaudited)		2,342,990		$	234			5,562,500	$	445	$	10,365,422		$	(5,366,098	)	$	5,000,003
Change in value of ordinary shares subject to possible redemption		226,126			23			—		—		2,261,237			—			2,261,260
Net loss		—			—			—		—		—			(2,261,261	)		(2,261,261	)
Balance – June 30, 2020 (unaudited)		2,569,116		$	257			5,562,500	$	445	$	12,626,659		$	(7,627,359	)	$	5,000,002

(1)

Includes the effect of the redemption of Class A ordinary shares on April 16, 2021. Shareholders holding 7,975,485 shares exercised their right to convert such shares into a pro-rata portion of the Trust Account (see Note 1).

The accompanying notes are an integral part of these unaudited condensed interim financial statements.

Table of Contents

SC HEALTH CORPORATION

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

	Three Months Ended March 31,
	Six Months Ended June 30,
	2021			2020
Cash Flows from Operating Activities:
Net (loss) income	$	(11,554,087	)	$	239,758
Net loss	$	(11,554,197	)	$	(2,021,503	)
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of warrant liabilities		1413,~~245~~447,~~592~~182			~~(54~~1,~~500~~689,000	)
Change in fair value of FPA liability		(2,950,567	)		~~160~~612,~~098~~025
Interest earned on marketable securities held in Trust Account		(58,~~480~~856	)		(~~557~~628,~~639~~159	)
Changes in operating assets and liabilities:
Prepaid expenses		(274,~~148~~191	)		5370,~~913~~350
Accounts payable and accrued expenses		66(32,~~993~~387	)		74(36,~~580~~509	)
Net cash provided by (used in) operating activities		(199,697	)		(83,790	)
Net cash used in operating activities		(1,024,634	)		(314,796	)
Cash Flows from Investing Activities:
Investment of cash in Trust Account		—			—
Cash withdrawn from Trust account for redemptions		80,711,908			—
Net cash provided by (used in) investing activities		—			—
Net cash provided by investing activities		80,711,908			—
Cash Flows from Financing Activities:
Proceeds from sale of Units, net of underwriting discounts paid		—			—
Proceeds from promissory note/advances – related party		935,000			—
Proceeds from sale of Private Placement Warrants		—			—
Redemption of Class A ordinary shares		(80,711,908	)		—
Proceeds from promissory note – related party		85,000			—
Net cash used in financing activities		(79,776,908	)		—
Payments of offering costs		—			—
Net Change in Cash		(89,634	)		(314,796	)
Net cash provided by (used in) financing activities		85,000			—
Net Change in Cash		(114,697	)		(83,790	)
Cash – Beginning		124,878			772,413
Cash – Ending	$	1035,~~181~~244		$	~~688~~457,~~623~~617
Non-Cash Investing and Financing Activities:
Payment of offering costs through promissory note	$	—		$	—
Change in value of Class A ordinary shares subject to possible redemption	$	(11,554,202	)	$	(2,021,500	)
Conversion of advances to promissory note	$	—		$	—
Initial classification of ordinary shares subject to possible redemption	$	—		$	—
Change in value of ordinary shares subject to possible redemption	$	(11,554,089	)	$	239,760
Deferred underwriting fee payable	$	—		$	—

The accompanying notes are an integral part of these unaudited condensed interim financial statements.

Table of Contents SC HEALTH CORPORATION NOTES TO CONDENSED INTERIM FINANCIAL STATEMENTS JUNE 30, 2021 (Unaudited)

SC HEALTH CORPORATION

NOTES TO CONDENSED INTERIM FINANCIAL STATEMENTS

MARCH 31, 2021

(Unaudited)

Note 1 — Description of Organization and Business Operations

SC Health Corporation (the “Company”) ~~was~~is a blank check company incorporated in the Cayman Islands on December 10, 2018. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization or similar business combination with one or more businesses (the “Business Combination”).

Although the Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination, the Company is focusing its search on companies with operations or prospects in the healthcare sector in the Asia Pacific region. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.

As of ~~March~~June 3130, 2021, the Company had not commenced any operations. All activity through ~~March~~June 3130, 2021 relates to the Company’s formation, the initial public offering (“Initial Public Offering”), which is described below, and, after the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering.

The registration statement for the Company’s Initial Public Offering was declared effective on July 11, 2019. On July 16, 2019, the Company consummated the Initial Public Offering of 15,000,000 units (the “Units” and, with respect to the shares of Class A ordinary shares included in the Units sold, the “Public Shares”), which is described in Note 3.

Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 5,000,000 warrants (the “Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant in a private placement to SC Health Holdings Limited, a Cayman Islands exempted company (the “Sponsor”), generating gross proceeds of $5,000,000, which is described in Note 4.

Following the closing of the Initial Public Offering on July 16, 2019, an amount of $150,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the “Trust Account”) and invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 180 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of Rule 2a-7 of the Investment Company Act of 1940, as amended (the “Investment Company Act”), as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account, as described below.

On August 2, 2019, in connection with the underwriters’ election to fully exercise their over-allotment option, the Company consummated the sale of an additional 2,250,000 Units at $10.00 per Unit and the sale of an additional 450,000 Private Placement Warrants at $1.00 per Private Placement Warrant, generating total gross proceeds of $22,950,000. Following the closing, an additional $22,500,000 of net proceeds was placed in the Trust Account, resulting in $172,500,000 held in the Trust Account.

Transaction costs amounted to $10,224,407, consisting of $3,450,000 of underwriting fees, $6,037,500 of deferred underwriting fees and $736,907 of other offering costs.

Substantially all of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants are intended to be applied toward consummating a Business Combination, and the Company’s management has broad discretion to identify targets for such a potential Business Combination and over the specific application of the funds held in the Trust Account if and when such funds are properly released from the Trust Account. The Company’s initial Business Combination must be with one or more target businesses that together have a fair market value of at least 80% of the net assets held in the Trust Account (net of amounts disbursed to management for working capital purposes and excluding deferred underwriting discount) at the time of the agreement to enter into a Business Combination. The Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to complete a Business Combination successfully.

The Company will provide its holders of the outstanding Public Shares (the “public shareholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The public shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account ($10.00 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The per-share amount to be distributed to public shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 5). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants.

Table of Contents

SC HEALTH CORPORATION

NOTES TO CONDENSED INTERIM FINANCIAL STATEMENTS

MARCH 31, 2021

(Unaudited)

The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the shares voted are voted in favor of the Business Combination. If a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its amended and restated memorandum and articles of association (“Memorandum and Articles of Association”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transactions is required by law, or the Company decides to obtain shareholder approval for business or legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each public shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks shareholder approval in connection with a Business Combination, the Sponsor, executive officers and directors (the “initial shareholders”) have agreed to vote their Founder Shares (as defined in Note 4) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination.

Notwithstanding the foregoing, if the Company seeks shareholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Memorandum and Articles of Association provides that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 20% or more of the Public Shares, without the prior consent of the Company.

The initial shareholders have agreed (a) to waive their redemption rights with respect to their Founder Shares and Public Shares held by them in connection with the completion of a Business Combination and (b) not to propose an amendment to the Memorandum and Articles of Association to modify the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the public shareholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.

The Company initially had until January 16, 2021, or such later date as a result of a shareholder vote to amend the Memorandum and Articles of Association, to complete a Business Combination (the “Combination Period”). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period.

On January 12, 2021, the Company held an extraordinary general meeting pursuant to which the Company’s shareholders approved extending the Combination Period from January 16, 2021 to April 16, 2021. In connection with the approval of the extension, no shareholders elected to redeem their shares for cash. On April 14, 2021, the Company held an extraordinary general meeting pursuant to which the Company’s shareholders approved extending the Combination Period from April 16, 2021 to August 16, 2021 (the “Extension Date”). In connection with the approval of the extension, shareholders elected to redeem 7,975,485 of Class A ordinary shares for a cash amounting $80,711,908.

The initial shareholders have agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the initial shareholders acquire Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).

In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i) $10.00 per share and (ii) the actual amount per Public Share held in the Trust Account if less than $10.00 per Public Share due to reductions in the value of the trust assets. This liability will not apply with respect to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account nor to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except for the Company’s independent auditors), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.

Table of Contents

SC HEALTH CORPORATION

NOTES TO CONDENSED INTERIM FINANCIAL STATEMENTS

MARCH 31, 2021

(Unaudited)

Going Concern

In connection with the Company’s assessment of going concern considerations in accordance with ~~FASB~~Financial Accounting Standard Board’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” ~~management~~the Company has ~~determined~~until ~~that~~August if16, 2021, to consummate the ~~Company~~proposed Business Combination. It is ~~unable~~uncertain tothat ~~raise~~the ~~additional~~Company ~~funds~~will be able to ~~alleviate~~consummate ~~liquidity~~the ~~needs~~proposed asBusiness ~~well~~Combination asby ~~complete~~this atime. ~~Business~~Additionally, ~~Combination~~the ~~during~~Company may not have sufficient liquidity to fund the ~~Combination~~working ~~Period,~~capital ~~then~~needs of the Company through one year from the issuance of these financial statements. If a business combination is not consummated by this date, there will ~~cease~~be ~~all~~a ~~operations except~~mandatory ~~for~~liquidation ~~the~~and ~~purpose~~subsequent dissolution of ~~liquidating~~the Company. ~~The~~Management has determined that the liquidity condition and ~~date for~~ mandatory liquidation, should a business combination not occur, and potential subsequent dissolution, ~~raise~~raises substantial doubt about the Company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after ~~the~~August ~~Combination~~16, ~~Period~~2021. The Company intends to complete athe proposed Business Combination before the mandatory liquidation date. However, there can be no assurance that the Company will be able to consummate any business combination by August 16, 2021.

Note 2 — Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed interim financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.

The accompanying unaudited condensed interim financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K/A for the year ended December 31, 2020 as filed with the SEC on May 26, 2021, which contains the audited financial statements and notes thereto. The interim results for the three and six months ended ~~March~~June 3130, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any future interim periods.

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

The Company will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of its Initial Public Offering, (b) in which the Company has total annual gross revenue of at least $1.07 billion, or (c) in which the Company is deemed to be a “large accelerated filer,” which means the market value of its ordinary shares that is held by non-affiliates exceeds $700 million as of the prior June 30th, and (2) the date on which the Company has issued more than $1.0 billion in non-convertible debt securities during the prior three-year period. References herein to “emerging growth company” shall have the meaning associated with it in the JOBS Act.

Table of Contents

SC HEALTH CORPORATION

NOTES TO CONDENSED INTERIM FINANCIAL STATEMENTS

MARCH 31, 2021

(Unaudited)

Use of Estimates

The preparation of the unaudited condensed interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed interim financial statements and the reported amounts of expenses during the reporting periods.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. ~~Accordingly~~One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liability. Such estimates may be subject to change as more current information becomes available and, accordingly, the actual results could differ significantly from those estimates.

Investments Held in Trust Account

AtAs ~~March~~of 31June 30, 2021 and December 31, 2020, ~~the~~ assets held in the Trust Account were invested in ~~money~~Money ~~market~~Market ~~funds~~Funds.

Class A Ordinary Shares Subject to Possible Redemption

The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Class A ordinary shares subject to mandatory redemption isare classified as a liability instrument and isare measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, at ~~March~~June 3130, 2021 and December 31, 2020, Class A ordinary shares subject to possible redemption is presented as temporary equity, outside of the shareholders’ equity section of the Company’s condensed balance sheets.

Offering Costs

Offering costs ~~consist~~consisted of legal, accounting, ~~underwriting fees~~ and other ~~costs~~expenses incurred through the Initial Public Offering that ~~are~~ were directly related to the Initial Public Offering. Offering costs ~~amounting to $10,224,407~~ were ~~charged~~allocated to ~~shareholders’~~the ~~equity~~separable ~~upon~~financial ~~the~~instruments ~~completion~~issued ofin the Initial Public Offering. ~~$328~~based on a relative fair value basis,~~858~~ ofcompared ~~the~~to ~~offering~~total proceeds received. Offering costs ~~were~~allocated ~~immediately~~to warrant liabilities were expensed ~~through~~as incurred in the ~~Statement~~statements of ~~Operations~~operations. inOffering ~~connection~~costs associated with the ~~initial~~Class ~~valuation~~A ofordinary shares issued were charged to shareholders’ equity upon the completion ~~warrant~~ of ~~liabilities~~the Initial Public Offering.

Warrant Liabilities

The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and FASB ASC Topic 815, “Derivatives and Hedging” (“ASC 815”).Company accounts for the Warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the Warrants and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the Warrants and are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815, including whether the Warrants and are indexed to the Company’s own ordinary shares and whether the holders of the Warrants could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of issuance of the Warrants as of each subsequent quarterly period end date while the Warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, such warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, liability-classified warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of such warrants are recognized as a non-cash gain or loss on the statements of operations.

The Company accounts for the Warrants in accordance with ASC 815-40 under which the Warrants do not meet the criteria for equity classification and must be recorded as liabilities. The fair value of the Public Warrants was initially estimated using a Monte Carlo simulation model with subsequent measurements estimated using the Public Warrants’ quoted market price. The Private Placement Warrants are valued using a Modified Black Scholes Option Pricing Model.

Income Taxes

The Company accounts for income taxes under ASC Topic 740, “Income Taxes,” which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of ~~March~~June 3130, 2021 and December 31, 2020, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.

The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company’s tax provision was zero for the periods ~~period~~ presented. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.

Table of Contents

SC HEALTH CORPORATION

NOTES TO CONDENSED INTERIM FINANCIAL STATEMENTS

MARCH 31, 2021

(Unaudited)

Net Income (Loss) per Ordinary Share

Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. The calculation of diluted income (loss) per ordinary share does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, (ii) the exercise of the over-allotment option and (iii) Private Placement Warrants since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. The warrants are exercisable to purchase 14,075,000 shares of Class A ordinary shares in the aggregate.

The Company’s condensed statements of operations ~~includes~~include a presentation of income (loss) per share for ordinary shares subject to possible redemption in a manner similar to the two-class method of income (loss) per share. Net income per share, basic and diluted, for Class A redeemable ordinary shares is calculated by dividing the interest income earned on the Trust Account, by the weighted average number of Class A redeemable ordinary shares outstanding since original issuance. Net loss per share, basic and diluted, for Class B non-redeemable ordinary shares is calculated by dividing the net loss, adjusted for income attributable to Class A redeemable ordinary shares, by the weighted average number of Class B non-redeemable ordinary shares outstanding for the period. Class B non-redeemable ordinary shares includes the Founder Shares as these shares do not have any redemption features and do not participate in the income earned on the Trust Account.

The following table reflects the calculation of basic and diluted net income (loss) per ordinary share (in dollars, except per share amounts):

	Three Months Ended March 31,
	Three Months Ended June 30,						Six Months Ended June 30,
	2021			2020			2021			2020
Redeemable Class A Ordinary Shares
Numerator: Earnings allocable to Redeemable Class A Ordinary Shares
Interest Income	$	53,~~480~~376		$	~~557~~70,~~639~~520		$	8,856		$	628,159
Net Earnings	$	5,480		$	557,639
Redeemable Net Earnings	$	3,376		$	70,520		$	8,856		$	628,159
Denominator: Weighted Average Redeemable Class A Ordinary Shares
Redeemable Ordinary Shares, Basic and Diluted		17,250,000			17,250,000
Redeemable Class A Ordinary Shares, Basic and Diluted		10,501,513			17,250,000			13,857,114			17,250,000
Earnings/Basic and Diluted Redeemable Class A Ordinary Shares	$	0.00		$	0.0300		$	0.00		$	0.04
Non-Redeemable Class B Ordinary Shares
Numerator: Net (Loss) Income minus Redeemable Net Earnings
Numerator: Net Income (Loss) minus Redeemable Net Earnings
Net (Loss) Income	$	(11,554,087	)	$	239,758
Net Income (Loss)	$	(110	)	$	(2,261,261	)	$	(11,554,197	)	$	(2,021,503	)
Redeemable Net Earnings		(5,480	)		(557,639	)
Less: Redeemable Net Earnings		(3,376	)		(70,520	)		(8,856	)		(628,159	)
Non-Redeemable Net Loss	$	(11,559,567	)	$	(317,881	)
Non-Redeemable Net Income (Loss)	$	(3,486	)	$	(2,331,781	)	$	(11,563,053	)	$	(2,649,662	)
Denominator: Weighted Average Non-Redeemable Class B Ordinary Shares
Non-Redeemable Class B Ordinary Shares, Basic and Diluted		5,562,500			5,562,500			5,562,500			5,562,500
Loss/Basic and Diluted Non-Redeemable Class B Ordinary Shares	$	(20.0800	)	$	(0.0642	)	$	(2.08	)	$	(0.48	)

As of March 31, 2021 and 2020, basic and diluted shares are the same as there are no securities that are dilutive to the shareholders.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance ~~Coverage~~ Corporation coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.

Fair Value of Financial Instruments

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” ~~approximates~~approximate the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature other than the warrant liabilities (see Note 8).

Fair Value Measurements

Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

•	Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;

•	Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as uoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

•	Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

Table of Contents

• Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

• Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.

Derivative Financial Instruments

The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.

Recent Accounting Standards

~~Management~~In August ~~does~~2020, ~~not~~the ~~believe~~FASB ~~that~~issued ~~any~~ASU ~~recently~~No. ~~issued~~2020-06, ~~but~~“Debt—Debt ~~not~~with ~~yet~~Conversion ~~effective~~and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”), which simplifies accounting ~~standards~~for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for fiscal years beginning after December 15, if2023, ~~currently~~including ~~adopted~~interim periods within those fiscal years, ~~would~~with ~~have~~early aadoption ~~material~~permitted. ~~effect~~The onCompany is currently assessing the ~~Company’s~~impact, ~~unaudited~~if ~~condensed~~any, ~~interim~~that ASU 2020-06 would have on its financial ~~statements~~position, results of operations or cash flows.

Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s unaudited condensed interim financial statements.

Table of Contents

SC HEALTH CORPORATION

NOTES TO CONDENSED INTERIM FINANCIAL STATEMENTS

MARCH 31, 2021

(Unaudited)

Note 3 — Public Offering

Pursuant to the Initial Public Offering, the Company sold 17,250,000 Units at a purchase price of $10.00 per Unit, inclusive of 2,250,000 Units sold to the underwriters on August 2, 2019 upon the underwriters’ election to fully exercise their over-allotment option. Each Unit consists of one Class A ordinary share and one-half of one redeemable warrant (“Public Warrant”). Each whole Public Warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment (see Note 67).

Note 4 — Related Party Transactions

Founder Shares

In December 2018, the Sponsor purchased 3,450,000 shares (the “Founder Shares”) of the Company’s Class B ordinary shares for an aggregate price of $25,000. On February 8, 2019, the Company completed a sub-division of its Class B ordinary shares, pursuant to which the Founder Shares were sub-divided into 4,312,500 shares with a par value of $0.00008 per share. All share and per-share amounts have been retroactively restated to reflect the sub-division. On July 9, 2019, the Company issued 1,250,000 Founder Shares to the Sponsor in connection with the forward purchase agreement (see Note 5) for par value, or $100, resulting in a total of 5,562,500 Founder Shares issued and outstanding of which an aggregate of up to 562,500 shares were subject to forfeiture to the extent that the underwriters’ over-allotment option was not exercised in full or in part, so that the initial shareholders would own, on an as-converted basis, 20% of the Company’s issued and outstanding shares after the Initial Public Offering (assuming no purchase by the initial shareholders of any Public Shares in the Initial Public Offering). As a result of the underwriters’ election to fully exercise their over-allotment option, 562,500 Founder Shares are no longer subject to forfeiture.

The Founder Shares will automatically convert into Class A ordinary shares upon consummation of a Business Combination on a one-for-one basis, subject to adjustments as described in Note 6.

The initial shareholders have agreed, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the earlier of (i) one year after the completion of the Company’s Business Combination or (ii) the date on which the Company completes a liquidation, merger, share exchange or other similar transaction after the Company’s Business Combination that results in all of the Company’s shareholders having the right to exchange their Class A ordinary shares for cash, securities or other property. Notwithstanding the foregoing, if the closing price of the Company’s Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share splits, share dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the Company’s Business Combination, the Founder Shares will be released from the lock-up.

Private Placement

Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 5,000,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant, for an aggregate purchase price of $5,000,000. On August 2, 2019, in connection with the underwriters’ exercise of the over-allotment option in full, the Company sold an additional 450,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant, for an aggregate purchase price of $450,000. Each Private Placement Warrant is exercisable to purchase one Class A ordinary share at a price of $11.50 per share. A portion of the proceeds from the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds of the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law), and the Private Placement Warrants and all underlying securities will expire worthless. At the date of the IPO, the fair value of the Private Placement Warrants was $0.62. The difference between the purchase price of $1 and the fair value at the IPO date of $0.62 was recorded within equity as a contribution in excess of the fair value of the Private Placement Warrants.

Table of Contents

SC HEALTH CORPORATION

NOTES TO CONDENSED INTERIM FINANCIAL STATEMENTS

MARCH 31, 2021

(Unaudited)

Administrative Support Agreement

The Company entered into an agreement whereby, commencing on July 16, 2019 and continuing through the earlier of the Company’s consummation of a Business Combination and its liquidation, the Company will pay an affiliate of the Sponsor a total of $10,000 per month for office space, secretarial and administrative support. For the three and six months ended ~~March~~June 3130, 2021 and 2020, the Company incurred $30,000 and $60,000, respectively, in fees for these services, respectively. As of ~~March~~June 3130, 2021 and December 31, 2020, $1040,000 and $10,000, respectively, of such fees, ~~respectively,~~ are included in accounts payable and accrued expenses in the accompanying condensed interim balance sheets.

Advance from Related Party

The Sponsor advanced the Company an aggregate of $32,313 to cover expenses related to the Initial Public Offering. The advances were non-interest bearing and due on demand. In January 2019, the advances were converted into a promissory note issued to the Sponsor (see below).

Promissory Note – Related Party

In January 2019, the Company issued an unsecured promissory note (the “Promissory Note”) to the Sponsor, pursuant to which the Company could borrow up to an aggregate principal amount of $300,000. The Promissory Note was non-interest bearing and payable on the earlier of December 31, 2019 or the completion of the Initial Public Offering. In January 2019, the Company transferred its outstanding advance from a related party in the amount of $32,313 into the Promissory Note. The outstanding balance of $254,595 under the Promissory Note was repaid as of December 31, 2019. Additionally, on December 30, 2020, the Sponsor deposited $100,000 into the operating bank account of the Company for working capital. An additional $50,000 and $35,000 was deposited into the operating bank statement form the Sponsor on March 22, 2021 and March 31, 2021, respectively. As of March 31, 2021, $185,000 in promissory notes from the Sponsor is outstanding.

On December 30, 2020, the Sponsor deposited $100,000 into the operating bank account of the Company for working capital. An additional $50,000, $35,000 and $850,000 was deposited into the operating bank statement for working capital from the Sponsor on March 22, 2021, March 31, 2021 and April 28, 2021, respectively. On May 25, 2021, the Company issued an unsecured promissory note (the “2021 Promissory Note”) in the principal amount of $2,000,000 to the Sponsor. The 2021 Promissory Note does not bear interest and is repayable in full upon consummation of the Company’s initial business combination. If the Company does not complete an initial business combination, the 2021 Promissory Note shall not be repaid and all amounts owed under it will be forgiven. The 2021 Promissory Note is subject to customary events of default, the occurrence of which automatically trigger the unpaid principal balance of the 2021 Promissory Note and all other sums payable with regard to the 2021 Promissory Note becoming immediately due and payable. The 2021 Promissory Note was issued pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended. The advances from the Sponsor on December 30, 2020, March 22, 2021, March 31, 2021 and April 28, 2021, were reclassified as withdrawals as part of the issued promissory note on May 25, 2021. As of June 30, 2021, $1,035,000 is outstanding under the promissory note.

Related Party Loans

In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor may, but is not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination or, at the lender’s discretion, up to $2,000,000 of such Working Capital Loans may be convertible into warrants of the post Business Combination entity at a price of $1.00 per warrant. The warrants would be identical to the Private Placement Warrants. As of ~~March~~June 3130, 2021, and December 31, 2020, no amounts were borrowed under the Working Capital Loans.

Note 5 — Commitments and Contingencies

Risks and Uncertainties

Management is continuing to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these condensed financial statements. The condensed interim financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Registration Rights

Pursuant to a registration rights agreement entered into on July 11, 2019, the holders of the Private Placement Warrants, the warrants that may be issued upon conversion of the Working Capital Loans, and the Founder Shares are entitled to registration rights with respect to such warrants and the ordinary shares underlying such warrants and Founder Shares. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities for sale under the Securities Act. In addition, the holders will have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

The Company granted the underwriters a 45-day option from the date of Initial Public Offering to purchase up to 2,250,000 additional Units to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions. In connection with the underwriters’ exercise of the over-allotment option in full on August 2, 2019, the underwriters purchased all 2,250,000 additional Units.

The underwriters are entitled to a deferred fee of $6,037,500, which will become payable to them from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.

Table of Contents

Forward Purchase Agreement

On July 9, 2019, SC Health Group Limited, an affiliate of the Sponsor, entered into a forward purchase agreement with the Company which provides for the purchase by SC Health Group Limited of an aggregate of 5,000,000 Class A ordinary shares, plus an aggregate of 1,250,000 redeemable warrants, each to purchase one Class A ordinary share at $11.50 per share, for an aggregate purchase price of $50,000,000, or $10.00 per Class A ordinary share and accompanying fraction of a warrant in a private placement to close concurrently with the closing of a Business Combination. On July 9, 2019, the Company issued 1,250,000 Founder Shares to the Sponsor in connection with the forward purchase agreement for par value, or $100, of which such shares would be transferred to SC Health Group Limited. The obligations under the forward purchase agreement do not depend on whether any Class A ordinary shares are redeemed by the Company’s public shareholders. As part of the Rockley Business Combination, the Company agreed with SC Health Group Limited that the Forward Purchase Agreement should be terminated and instead of purchasing $50,000,000 of Class A ordinary shares pursuant to the forward purchase agreement, SC Health Group Limited would instead enter into the Investor Subscription Agreement referenced below and, pursuant to that agreement, has agreed to purchase an aggregate of $50,000,000 shares in Rockley Photonics Holdings Limited. In connection with the termination of the Forward Purchase Agreement, the company recognized a gain of $2,950,567 with the first quarter of 2021, which is included in the change in FPA liability on the accompanying unaudited condensed interim ~~statement~~statements of operations.

Table of Contents

SC HEALTH CORPORATION

NOTES TO CONDENSED INTERIM FINANCIAL STATEMENTS

MARCH 31, 2021

(Unaudited)

Business Combination Agreement

On January 5, 2021, the Company announced that it had entered into a non-binding letter of intent (the “Letter of Intent”) with a next generation technology developer (the “Target”) relating to a proposed business combination transaction. The Target has developed a technology targeting consumer healthcare applications, and the Company believes the Target is a compelling investment opportunity given its cutting-edge technology and commercial opportunity. Completion of the proposed transaction is subject to the completion of due diligence, the negotiation and execution of a definitive agreement and satisfaction of the conditions therein, including approval of the transaction by the Company’s shareholders.

On March 19, 2021, the Company entered into a Business Combination Agreement and Plan of Merger (the “Business Combination Agreement”), by and among Rockley Photonics Limited, a company incorporated under the laws of England and Wales with company number 08683015 (the “Rockley”), Rockley Photonics Holdings Limited, an exempted company incorporated in the Cayman Islands with limited liability (“HoldCo”), and Rockley Mergersub Limited, an exempted company incorporated in the Cayman Islands with limited liability and a direct wholly owned subsidiary of HoldCo (“Merger Sub”). The Business Combination Agreement and the transactions contemplated thereby (the “Rockley Business Combination”) were approved by our board of directors and the boards of directors of each of HoldCo, Merger Sub and Rockley.

The Business Combination Agreement provides for, among other things, the following transactions on the closing date: (i) the Company carries out a scheme of arrangement in the UK courts pursuant to which all of the Company’s shares (including those issued prior to the scheme as a result of the conversion of convertible loan notes and the exercise of warrants) will be cancelled or transferred by the Company’s shareholders in exchange for shares in HoldCo; (ii) the holders of options over shares in the Company will be invited to roll their options into new options over shares in HoldCo; (iii) to the extent convertible loan notes issued by the Company do not convert into shares in the Company prior to the effectiveness of the scheme described in clause (i) above, such notes will, depending on which form the scheme of arrangement takes, either be (a) novated to HoldCo (resulting in HoldCo becoming responsible to issue HoldCo ordinary shares on exercise) and the consideration for the novation shall be an inter-company loan between the Company and HoldCo, or (b) acquired by HoldCo in exchange for the issue of new convertible loan notes by HoldCo to each convertible loan note holder; (iv) the holders of warrants over shares in the Company (other than warrants that by their terms will be replicated at HoldCo in exchange for market value consideration) will be notified that if they do not exercise their warrants for shares in the Company prior to the effectiveness of the scheme described in clause (i) above, then those warrants will lapse; (v) HoldCo will complete a ‘stock-split’ to prepare its share capital for Merger Sub’s merger into SC Health; (vi) certain investors will subscribe for and purchase an aggregate of $150,000,000 of shares in HoldCo; (vii) Merger Sub will merge with and into SC Health, with SC Health surviving the merger and becoming a direct wholly-owned subsidiary of HoldCo; and (viii) the shares and warrants in SC Health will be exchanged for shares and warrants in HoldCo.

In accordance with the terms and subject to the conditions of the Business Combination Agreement, (i) the existing holders of securities in the Company will exchange their securities for new securities in HoldCo; and (ii) HoldCo will split its stock such that the number of shares in (together with any other securities in or convertible for securities in) HoldCo after the stock split will be equal to $1,148,114,113 divided by $10.00. Certain PIPE investors will subscribe for shares in HoldCo and the warrants in SC Health (each $10.00 shares) will then be exchanged for shares in HoldCo.

Concurrently with the execution of the Business Combination Agreement, the Company and HoldCo entered into subscription agreements (the “Investor Subscription Agreements”) with certain investors and individuals, including, among others, SC Health Group Limited (an affiliate of the Sponsor), Medtronic, Senvest Management LLC and UBS O’Connor. Pursuant to the Investor Subscription Agreements, each investor agreed to subscribe for and purchase, and HoldCo agreed to issue and sell an aggregate of $150,000,000 shares in HoldCo, which will take effect immediately prior to the closing of the Rockley Business Combination.

Previously the Company had entered into a forward purchase agreement with SC Health Group Limited which provided for the purchase by SC Health Group Limited of an aggregate of 5,000,000 Class A ordinary shares, plus an aggregate of 1,250,000 redeemable warrants to purchase one Class A ordinary share at $11.50 per share, for an aggregate purchase price of $50,000,000, or $10.00 per Class A ordinary share and accompanying fraction of a warrant in a private placement to close concurrently with the closing of our initial business combination. As part of the Rockley Business Combination, the Company agreed with SC Health Group Limited that the Forward Purchase Agreement should be terminated and instead of purchasing $50,000,000 of Class A ordinary shares pursuant to the forward purchase agreement, SC Health Group Limited would instead enter into the Investor Subscription Agreement referenced above and, pursuant to that agreement, has agreed to purchase an aggregate of $50,000,000 shares in HoldCo.

Note 6 — Shareholders’ Equity

Preference Shares — The Company is authorized to issue to 1,000,000 preference shares with a par value of $0.0001 per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. At ~~March~~June 3130, 2021 and December 31, 2020, there were no preference shares issued or outstanding.

Class A Ordinary Shares — The Company is authorized to issue 180,000,000 Class A ordinary shares with a par value of $0.0001 per share. Holders of the Company’s Class A ordinary shares are entitled to one vote for each share. At ~~March~~June 3130, 2021 and December 31, 2020, there were 4,~~344~~440,~~617~~334 and 3,189,208 Class A ordinary shares issued and outstanding, excluding 124,~~905~~834,~~383~~181 and 14,060,792 Class A ordinary shares subject to possible redemption, respectively.

Class B Ordinary Shares — The Company is authorized to issue to 25,000,000 Class B ordinary shares with a par value of $0.00008 per share. Holders of Class B ordinary shares are entitled to one vote for each share. At ~~March~~June 3130, 2021 and December 31, 2020, there were 5,562,500 ordinary shares issued and outstanding.

Holders of Class B ordinary shares will have the right to elect the Company’s directors prior to or in connection with the completion of a Business Combination. Holders of Class A ordinary shares and Class B ordinary shares will vote together as a single class on all other matters submitted to a vote of shareholders, except as required by law.

Table of Contents

SC HEALTH CORPORATION

NOTES TO CONDENSED INTERIM FINANCIAL STATEMENTS

MARCH 31, 2021

(Unaudited)

The Class B ordinary shares will automatically convert into Class A ordinary shares at the time of a Business Combination on a one-for-one basis, subject to adjustment as follows. The Class B ordinary shares will automatically convert into Class A ordinary shares on the first business day following the consummation of a Business Combination at a ratio such that the total number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as-converted basis, 20% of the total number of Class A ordinary shares outstanding upon completion of this offering, plus the total number of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of a Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, or to be issued, to any seller in a Business Combination and any warrants issued in a private placement to the Sponsor or an affiliate of the Sponsor upon conversion of Working Capital Loans.

NOTE 7 — ~~Warrants~~Warrant Liabilities

~~Warrants~~ —As ~~Public Warrants may only be exercised for a whole number~~ of ~~shares.~~June No30, ~~fractional~~2021, ~~warrants were issued upon separation of~~ the ~~Units,~~Company ~~which occurred~~had ~~on September 3~~8, ~~2019~~625,000 ~~and only whole warrants will trade. The~~ Public Warrants ~~will~~and ~~become exercisable on the later of (a) 30 days after the completion of a Business Combination or (b) 12 months from the closing of the Initial Public~~5,450,000 ~~Offering.~~ Private ~~The~~Placement ~~Public~~ Warrants ~~will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation~~outstanding.

Public Warrants may only be exercised for a whole number of shares. No fractional warrants were issued upon separation of the Units, which occurred on September 3, 2019, and only whole warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination or (b) 12 months from the closing of the Initial Public Offering. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.

The Company will not be obligated to deliver any Class A ordinary shares pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act with respect to the Class A ordinary shares underlying the Public Warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations described below with respect to registration. No warrant will be exercisable and the Company will not be obligated to issue a Class A ordinary share upon exercise of a Public Warrant unless the Class A ordinary share issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants.

The Company has agreed that as soon as practicable, but in no event later than thirty (30) business days after the closing of a Business Combination, it will use its best efforts to file with the SEC a registration statement for the registration, under the Securities Act, of the Class A ordinary shares issuable upon exercise of the Public Warrants. The Company will use its best efforts to cause the same to become effective and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the warrants in accordance with the provisions of the warrant agreement. If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the sixtieth (60th) day after the closing of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption.

Redemption of Warrants for Cash. Once the warrants become exercisable, the Company may redeem the Public Warrants:

•

in whole and not in part;

•

at a price of $0.01 per warrant;

•

upon not less than 30 days’ prior written notice of redemption; and

•

if, and only if, the reported last sales price of the Company’s Class A ordinary shares equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.

If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws.

Redemption of Warrants for Class A Ordinary Shares. Commencing ninety days after the warrants become exercisable, the Company may redeem the outstanding Public Warrants:

•

in whole and not in part;

•

at a price equal to a number of Class A ordinary shares to be determined, based on the redemption date and the fair market value of the Company’s Class A ordinary shares;

•

upon a minimum of 30 days’ prior written notice of redemption;

•

if, and only if, the last reported sale price of the Company’s Class A ordinary shares equals or exceeds $10.00 per share (as adjusted for share splits, share dividends, reorganizations, recapitalizations and the like) on the trading day prior to the date on which the Company sends the notice of redemption to the warrant holders;

•

if, and only if, the Private Placement Warrants are also concurrently exchanged at the same price (equal to a number of Class A ordinary shares) as the outstanding Public Warrants; and

•

if, and only if, there is an effective registration statement covering the Class A ordinary shares issuable upon exercise of the warrants and a current prospectus relating thereto available throughout the 30-day period after written notice of redemption is given

Table of Contents

SC HEALTH CORPORATION

NOTES TO CONDENSED INTERIM FINANCIAL STATEMENTS

MARCH 31, 2021

(Unaudited)

If the Company calls the Public Warrants for redemption, management will have the option to require any holder that wishes to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of ordinary shares at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.

In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company) and, (i) in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance, and (ii) to the extent that such issuance is made to SIN Capital Group Pte. Ltd., an affiliate of the Company and the Sponsor or its affiliates, without taking into account the transfer of Founder Shares or Private Placement Warrants (including if such transfer is effectuated as a surrender to the Company and subsequent reissuance by the Company) by the Sponsor in connection with such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z) the volume weighted average trading price of our Class A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates a Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price.

The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants and the Class A ordinary shares issuable upon the exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants will be exercisable on a cashless basis and be non-redeemable (for cash) so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.

Note 8 — Fair Value Measurements

The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:

Level 1:

Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2:

Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.

Level 3:

Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.

The Company classifies its U.S. Treasury and equivalent securities within the Trust Account as held-to-maturity in accordance with ASC Topic 320 “Investments - Debt and Equity Securities.” Held-to-maturity securities are those securities which the Company has the ability and intent to hold until maturity. Held-to-maturity treasury securities are recorded at amortized cost on the accompanying condensed balance sheets and adjusted for the amortization or accretion of premiums or discounts.

At ~~March~~June 3130, 2021, assets held in the Trust Account were comprised of $~~174~~93,~~547~~838,~~492~~960 in money market funds, which are invested in U.S. Treasury Securities. At December 31, 2020, assets held in the Trust Account ~~were~~ were comprised of $174,542,012 in money market funds, which are invested in U.S. Treasury Securities, For the money market funds that the Trust Accounts are invested in, the fair market value of the money market funds is equivalent to the amortized cost value. During the three and six months ended ~~March~~June 3130, 2021, ~~and~~or ~~the year ended December 31,~~ 2020, the Company did not withdraw any interest income from the Trust Account.

Table of Contents

SCAt ~~HEALTH~~June ~~CORPORATION~~30, 2021 and December 31, 2020, there were 5,450,000 Public Warrants and 8,625,000 Private Placement Warrants outstanding. Additionally, there were 0 and 5,000,000 Class A ordinary shares with an accompanying fractional warrant outstanding in relation to the Forward Purchase Agreement as of June 30, 2021, and December 31, 2020 outstanding, respectively.

~~NOTES~~The TOfollowing ~~CONDENSED~~table ~~INTERIM~~presents ~~FINANCIAL~~information ~~STATEMENTS~~about the Company’s assets and liabilities that are measured at fair value on a recurring basis at June 30, 2021 and December 31, 2020 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.

MARCH 31, 2021

Description	Level		June 30, 2021		December 31, 2020
Assets:
Marketable securities held in Trust Account – U.S. Treasury Securities Money Market Fund		1	$	93,838,960	$	174,542,012

Liabilities:
Private Placement Warrants		3	$	14,304,182	$	7,412,000
Public Warrants		1		18,198,750		11,643,750
Forward Purchase Agreement (FPA)		3		—		2,950,567

~~(Unaudited)~~The Warrants and FPA were accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities on the condensed balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities and FPA in the condensed statements of operations.

AtThe ~~March~~Company ~~31,~~established ~~2021~~the initial fair value for the private and ~~December~~public ~~31,~~warrants ~~2020,~~and ~~there~~the ~~were~~FPA 5on July 16,~~450~~ 2019,~~000~~ ~~Public~~the ~~Warrants~~date ~~and~~of 8the Company’s Initial Public Offering,~~625,000~~ using various valuation methodologies. The Private Placement Warrants ~~outstanding.~~were ~~Additionally~~initially measured using a Modified Black-Scholes, ~~there~~the public warrants were 0initially ~~and~~measured ~~5,000,000~~using ~~Class~~a AMonte ~~ordinary~~Carlo ~~shares~~simulation, ~~with~~and ~~an accompanying~~the ~~fractional~~FPA ~~warrant~~was ~~outstanding~~initially inmeasured ~~relation~~using toa ~~the~~forward ~~Forward~~valuation ~~Purchase~~model. ~~Agreement~~The asinitial measurement of ~~March~~the ~~31,~~liabilities ~~2021,~~was ~~and~~classified ~~December~~as Level ~~31,~~3 ~~2020~~due ~~outstanding,~~to ~~respectively~~the use of unobservable inputs.

The ~~following~~subsequent ~~table~~measurement ~~presents~~of ~~information about~~ the ~~Company’s~~private warrants ~~assets~~is ~~and~~performed ~~liabilities~~using ~~that~~Modified ~~are~~Black-Scholes ~~measured~~Model. atThe ~~fair~~public ~~value~~warrants onare asubsequently ~~recurring~~measured ~~basis~~ at ~~March~~the ~~31,~~trading ~~2021~~stock ~~and~~price ~~December~~at ~~31, 2020 and indicates~~ the ~~fair~~end ~~value hierarchy~~ of the ~~valuation~~reporting ~~inputs the Company utilized to determine such fair value~~periods. The ~~gross~~FPA ~~holding~~is ~~gains~~no ~~and~~longer ~~fair~~measured ~~value~~due ~~of held-~~to~~-maturity~~ ~~securities~~the attermination ~~March~~described in ~~31,~~Note ~~2021 and December 31, 2020 are as follows:~~5.

Description	Level		March 31, 2021		December 31, 2020
Assets:
Marketable securities held in Trust Account – U.S. Treasury Securities Money Market Fund		1	$	174,547,492	$	174,788,957
Liabilities:
Private Placement Warrants		3	$	17,000,092	$	7,412,000
Public Warrants		1		16,301,250		11,643,750
Forward Purchase Agreement Liability		3		—		2,950,567

The key inputs into the Modified Black-Scholes Model for the Private Placement Warrants were as follows at June 30, 2021 and December 31, 2020:

The Warrants and FPA were accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities on the balance sheet. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the consolidated statement of operations.

Input	June 30, 2021			December 31, 2020
Risk-free interest rate		0.91	%		0.40	%
Time to Maturity (Years)		5.25			5.29
Implied volatility		40.0	%		19.00	%
Exercise price	$	11.50		$	11.50
Implied Stock Price	$	10.08		$	10.25

The ~~Company~~following ~~established~~table ~~the~~presents ~~initial fair value for~~ the ~~private~~changes ~~and~~in ~~public warrants and~~ the ~~FPA~~fair onvalue ~~July 16, 2019, the date~~ of ~~the Company’s Initial Public Offering, using various valuation methodologies. The Private~~ ~~Placement~~ level ~~Warrants~~3 ~~were~~warrant ~~initially measured using a Black-Scholes, the public warrants were initially measured using a Monte Carlo simulation,~~ and ~~the~~ FPA ~~was initially measured using a forward valuation model. The initial measurement of the~~ liabilities ~~was classified as Level 3 due to the use of unobservable inputs.~~:

The Warrants are subsequently measured at fair value on a recurring basis. The subsequent measurement of the private warrants is performed using Black-Scholes Model. The public warrants are subsequently measured at the trading stock price at the end of the reporting period. The FPA is no longer measured due to the termination described in Note 5.

	Forward Purchase Agreement			Private Placement Warrants
Fair value as of December 31, 2020	$	2,950,567		$	7,412,000
Change in fair value		—			9,588,092
Termination of FPA		(2,950,567	)		—
Fair value as of March 31, 2021		—		$	17,000,092
Change in fair value		—			(2,695,910	)
Fair value as of June 30, 2021	$	—		$	14,304,182

~~The~~There ~~key~~were ~~inputs~~no ~~into~~transfers ~~the~~in ~~Black-Scholes~~or ~~Model~~out ~~for~~of ~~the~~Level ~~Private~~3 ~~Placement~~from ~~Warrants~~other ~~were~~levels asin ~~follows~~the atfair ~~March~~value ~~31,~~hierarchy ~~2021~~during the three and ~~December~~six 31months ended June 30, ~~2020:~~2021.

Input	March 31, 2021			December 31, 2020
Risk-free interest rate		0.98	%		0.40	%
Time to Maturity (Years)		5.25			5.29
Implied volatility		38.00	%		19.00	%
Exercise price	$	11.50		$	11.50
Implied Stock Price	$	10.08		$	10.25

The following table presents the changes in the fair value of warrant liabilities:

	Forward Purchase Agreement			Private Placement Warrants
Fair value as of December 31, 2020	$	2,950,567		$	7,412,000
Change in valuation inputs or other assumptions		(2,950,567	)		9,588,092
Fair value as of March 31, 2021	$	—		$	17,000,092

Note 9 — Subsequent Events

The Company evaluated subsequent events and transactions that occurred after the condensed balance sheet date up to the date that the unaudited condensed interim financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed interim financial statements.

Table of Contents

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

References in this report (the “Quarterly Report”) to “we,” “us” or the “Company” refer to SC Health Corporation. References to our “management” or our “management team” refer to our officers and directors, references to the “Sponsor” refer to SC Health Holdings Limited. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the financial statements and the notes thereto contained elsewhere in this Quarterly Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Special Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q includes “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act that are not historical facts, and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements other than statements of historical fact included in this Form 10-Q including statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the Company’s financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as “expect,” “believe,” “anticipate,” “intend,” “estimate,” “seek” and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of the Company’s Annual Report on Form 10-K/A for the year ending December 31, 2020 filed with the SEC on May 26, 2021. The Company’s securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Overview

We are a blank check company incorporated on December 10, 2018 as a Cayman Islands exempted company and incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar Business Combination with one or more businesses. We intend to complete our Business Combination using cash from the proceeds from our Initial Public Offering and the sale of the Private Placement Warrants, our shares, debt or a combination of cash, equity and debt.

We expect to continue to incur significant costs in the pursuit of our acquisition plans. We cannot assure you that our plans to complete a Business Combination will be successful.

Recent Developments

On March 19, 2021 we entered into a Business Combination Agreement and Plan of Merger (the “Business Combination Agreement”), by and among Rockley Photonics Limited, a company incorporated under the laws of England and Wales with company number 08683015 (the “Rockley”), Rockley Photonics Holdings Limited, an exempted company incorporated in the Cayman Islands with limited liability (“HoldCo”), and Rockley Mergersub Limited, an exempted company incorporated in the Cayman Islands with limited liability and a direct wholly owned subsidiary of HoldCo (“Merger Sub”). The Business Combination Agreement and the transactions contemplated thereby (the “Rockley Business Combination”) were approved by our board of directors and the boards of directors of each of HoldCo, Merger Sub and Rockley.

Results of Operations

We have neither engaged in any operations nor generated any revenues to date. Our only activities from inception to ~~March~~June 3130, 2021 were organizational activities, those necessary to prepare for the Initial Public Offering, described below, and, after the Initial Public Offering, identifying a target company for a Business Combination at the earliest. We do not expect to generate any operating revenues until after the completion of our Business Combination. We generate non-operating income in the form of interest income on marketable securities held in the Trust Account. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses in connection with completing a Business Combination.

For the three months ended ~~March~~June 3130, 2021, we had a net loss of $11110,~~554,087,~~ which consisted of ~~operating expenses of $264,542 and~~ a change in fair value of warrant liabilities 14of $798,~~245,592,~~410 ~~offset by~~ and interest earned on investments held in the Trust Account of $53,~~480~~376 ~~and~~offset aby ~~gain~~operating onexpenses ~~the termination~~ of ~~the forward purchase agreement of~~ $2801,~~950,567, which is included in the change in fair value of the Forward Purchase Agreement~~896.

For the ~~three~~six months ended ~~March~~June 3130, ~~2020~~2021, we had a net ~~income~~loss of $~~239~~11,~~758~~554,197, which consisted of ~~interest~~operating ~~earned~~expenses ~~on investments held in the Trust Account~~ of $~~557~~1,~~639~~066,438 and a change in ~~the~~ fair value of warrant liabilities of $5413,~~500~~447,182, offset by ~~operating~~ ~~expenses~~interest earned on investments held in the Trust Account of $~~212~~8,~~283~~856 and a ~~change~~gain inon the ~~fair~~termination ~~value~~ of the forward purchase agreement of $~~160~~2,~~098~~950,567, which is included in the change in fair value of the Forward Purchase Agreement.

For the three months ended June 30, 2020, we had net loss of $2,261,261, which consisted of operating expenses of $136,354, change in the fair value of the forward purchase agreement of $451,927, and a change in the fair value of warrant liabilities of $1,743,500, offset by interest earned on investments held in the Trust Account of $70,520.

For the six months ended June 30, 2020, we had a net loss of $2,021,503, which consisted of operating expenses of $348,637, change in the fair value of the forward purchase agreement of $612,025, and a change in the fair value of warrant liabilities of $1,689,000, offset by interest earned on investments held in the Trust Account of $628,159.

Table of Contents

Liquidity and Capital Resources

On July 16, 2019, we consummated the Initial Public Offering of 15,000,000 Units at a price of $10.00 per Unit, generating gross proceeds of $150,000,000. Simultaneously with the closing of the Initial Public Offering, we consummated the sale of an aggregate of 5,000,000 Private Placement Warrants to our Sponsor at a price of $1.00 per warrant, generating gross proceeds of $5,000,000.

On August 2, 2019, in connection with the underwriters’ full exercise of their over-allotment option, we consummated the sale of an additional 2,250,000 Units and the sale of an additional 450,000 Private Placement Warrants, generating total gross proceeds of $22,950,000.

Following the Initial Public Offering, the exercise of the over-allotment option and the sale of the Private Placement Warrants, a total of $172,500,000 was placed in the Trust Account. We incurred $10,224,407 in transaction costs, including $3,450,000 of underwriting fees, $6,037,500 of deferred underwriting fees and $736,907 of other costs in connection with the Initial Public Offering and the sale of the Private Placement Warrants.

For the ~~three~~six months ended ~~March~~June 3130, 2021, net cash used in operating activities was $~~199~~1,~~697~~024,634. Net loss of $11,554,~~087~~197 was impacted by interest earned on investments of $58,~~480~~856 and a gain on the termination of the ~~forward~~ forward purchase agreement of $2,950,567, which is included in the change in fair value of the Forward Purchase Agreement, offset by a change in the fair value of warrant liabilities of $1413,~~245~~447,~~592~~182. Changes in operating assets and liabilities used $6441,~~845~~ 804 of cash from operating activities.

For the ~~three~~six months ended ~~March~~June 3130, 2020, net cash used in operating activities was $83314,~~790~~796. Net ~~income~~loss of $~~239~~2,~~758~~021,503 was ~~impacted~~affected by interest earned on investments of $628,159, offset by a change in the fair value of the forward purchase agreement of $~~160~~612,~~098,~~025 ~~offset by interest earned on investments of $557,639~~ and a change in the fair value warrant liabilities of $541,~~500~~689,000. Changes in operating assets and liabilities provided $~~128~~33,~~493~~841 of cash from operating activities.

In April 2021, shareholders redeemed 7,975,485 Class A ordinary shares at approximately $10.12 per share, for an aggregate redemption of $80,711,908. At ~~March~~June 3130, 2021, we had investments held in the Trust Account of $~~174~~93,~~547~~838,~~492~~960. We intend to use substantially all of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account (less taxes payable (if applicable) and deferred underwriting commissions) to complete our Business Combination. To the extent that our shares or debt is used, in whole or in part, as consideration to complete our Business Combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the post-Business Combination entity, make other acquisitions and pursue our growth strategies.

At ~~March~~June 3130, 2021, we had cash of $1035,~~181~~244 held outside of the Trust Account. We intend to use the funds held outside the Trust Account primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, properties or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, and structure, negotiate and complete a Business Combination.

In order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, our Sponsor or an affiliate of our Sponsor or certain of our officers and directors may, but are not obligated to, loan us funds as may be required. If we complete a Business Combination, we would repay such loaned amounts. In the event that a Business Combination does not close, we may use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from our Trust Account would be used for such repayment. Up to $2,000,000 of such loans may be convertible into warrants identical to the Private Placement Warrants, at a price of $1.00 per warrant at the option of the lender.

We do not believe we will need to raise additional funds in order to meet the expenditures required for operating our business. However, if our estimate of the costs of identifying a target business, undertaking in-depth due diligence and negotiating and consummating a Business Combination are less than the actual amount necessary to do so, we may have insufficient funds available to operate our business prior to our Business Combination. Moreover, we may need to obtain additional financing either to complete our Business Combination or because we become obligated to redeem a significant number of our public shares upon consummation of our Business Combination, in which case we may issue additional securities or incur debt in connection with such Business Combination. Subject to compliance with applicable securities laws, we would only complete such financing simultaneously with the completion of our Business Combination. If we are unable to complete our Business Combination because we do not have sufficient funds available to us, we will be forced to cease operations and liquidate the Trust Account. In addition, following our Business Combination, if cash on hand is insufficient, we may need to obtain additional financing in order to meet our obligations.

In the event that we are unable to close a Business Combination within the 18 months following the closing of the Initial Public Offering, the escrow agent under an escrow created by our Sponsor or an affiliate will be authorized and instructed to transfer $1.00 per whole public warrant, to holders of public warrants other than our Sponsor and its affiliates, at the same time as we redeem our public shares, and all public warrants will expire worthless.

In connection with the Initial Public Offering, our Sponsor deposited cash funds into an escrow account with J.P. Morgan Chase Bank, N.A. in an amount equal to $8,625,000. The funds held in the escrow account may be used to pay $1.00 per public warrant (other than public warrants held by our Sponsor and its affiliates) as described above. The funds in the escrow account will not be held in trust or comprise any portion of any pro-rata distribution of our trust account. The escrow of the cash funds are governed by an escrow agreement.

Following a repurchase or payment to holders of public warrants, any amounts remaining in the escrow account will be returned to our Sponsor or its affiliate.

Table of Contents

Going Concern

In connection with the Company’s assessment of going concern considerations in accordance with FASB’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that if the Company is unable to raise additional funds to alleviate liquidity needs as well as complete a Business Combination during the Combination Period, then the Company will cease all operations except for the purpose of liquidating. The liquidity condition and date for mandatory liquidation and subsequent dissolution raise substantial doubt about the Company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after the Combination Period.

Off-Balance Sheet Financing Arrangements

We have no obligations, assets or liabilities, which would be considered off-balance sheet arrangements as of ~~March~~June 3130, 2021. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.

Contractual Obligations

We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities, other than as described below.

We entered into an agreement to pay our Sponsor a monthly fee of $10,000 for office space, secretarial and administrative support to the Company. We began incurring these fees on July 16, 2019 and will continue to incur these fees on a monthly basis until the earlier of the completion of the Business Combination and the Company’s liquidation.

We have an agreement to pay the underwriters a deferred fee of $6,037,500, which will become payable to them from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.

Additionally, SC Health Group Limited, an affiliate of our Sponsor, entered into a forward purchase agreement with us which provides for the purchase by SC Health Group Limited of an aggregate of 5,000,000 Class A ordinary shares, plus an aggregate of 1,250,000 redeemable warrants, each to purchase one Class A ordinary share at $11.50 per share, for an aggregate purchase price of $50,000,000, or $10.00 per Class A ordinary share and accompanying fraction of a warrant in a private placement to close concurrently with the closing of a Business Combination. The obligations under the forward purchase agreement do not depend on whether any Class A ordinary shares are redeemed by our public shareholders.

Critical Accounting Policies

The preparation of condensed interim financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates. We have identified the following critical accounting policies:

Warrant ~~Liability~~Liabilities and FPA Liabilities

The Company accounts for the Warrants and FPA as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the Warrants and the FPA and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the Warrants and FPA are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815, including whether the Warrants and FPA are indexed to the Company’s own ordinary shares and whether the holders of the Warrants could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of issuance of the Warrants and execution of the FPA and as of each subsequent quarterly period end date while the Warrants and FPA are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, such warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, liability-classified warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of such warrants are recognized as a non-cash gain or loss on the statements of operations.

Class A Ordinary Shares Subject to Possible Redemption

We account for our Class A ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Class A ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. Our Class A ordinary shares feature certain redemption rights that are considered to be outside of our control and subject to occurrence of uncertain future events. Accordingly, Class A ordinary shares subject to possible redemption is presented as temporary equity, outside of the shareholders’ equity section of our balance sheets.

Table of Contents

Net Income (Loss) per Ordinary Share

We apply the two-class method in calculating earnings per share. Net income (loss) per ordinary share, basic and diluted for Class A redeemable ordinary shares is calculated by dividing the interest income earned on the Trust Account by the weighted average number of Class A redeemable ordinary shares outstanding for the period. Net income (loss) per ~~common~~ordinary share, basic and diluted for Class B non-redeemable ordinary shares is calculated by dividing the net income (loss), less income attributable to Class A redeemable ordinary shares, by the weighted average number of Class B non-redeemable ordinary shares outstanding for the periods presented.

Recent Accounting Standards

~~Management~~In ~~does~~August ~~not~~2020, ~~believe~~the ~~that~~FASB ~~any~~issued ~~recently~~ASU ~~issued~~No. 2020-06, ~~but~~“Debt—Debt ~~not~~with ~~yet~~Conversion ~~effective~~and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”), which simplifies accounting ~~standards~~for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for fiscal years beginning after December 15, if2023, including interim periods within those fiscal years, with early adoption permitted. The Company is currently ~~adopted~~assessing the impact, if any, that ASU 2020-06 would have aon ~~material~~its ~~effect~~financial onposition, ~~our~~results ~~unaudited~~of ~~condensed~~operations ~~interim~~or ~~financial~~cash ~~statements~~flows.

Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on our unaudited condensed interim financial statements.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As of ~~March~~June 3130, 2021, we were not subject to any market or interest rate risk. Following the consummation of our Initial Public Offering, the net proceeds received into the Trust Account, have been invested in U.S. government treasury bills, notes or bonds with a maturity of 180 days or less or in certain money market funds that invest solely in US treasuries. Due to the short-term nature of these investments, we believe there will be no associated material exposure to interest rate risk.

ITEM 4.

CONTROLS AND PROCEDURES

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

Evaluation of Disclosure Controls and Procedures

Disclosure controls are procedures that are designed with the objective of ensuring that information required to be disclosed in our reports filed under the Exchange Act is recorded, processed, summarized, and reported within the time period specified in the SEC’s rules and forms. Disclosure controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including the chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure. InOur ~~connection with this Amendment, our~~ management ~~re-~~evaluated, with the participation of our current chief executive officer and ~~chief~~ chief financial officer (our “Certifying Officers”), the effectiveness of our disclosure controls and procedures ~~as of March 31~~, ~~2021,~~ pursuant to Rule 13a-15(b) under the Exchange Act. Based upon that evaluation, and solely due to the material weakness in ~~our~~ our internal control over financial reporting that led to the Company’s restatement of its financial statements to reclassify the Company’s warrants as described in our Form 10-K/A filed with the ~~Explanatory~~SEC ~~Note~~on toMay ~~this~~26, ~~Amendment~~2021, our Certifying Officers concluded that, as of ~~March~~June 3130, 2021, our disclosure controls and procedures were not effective.

We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Management performed an analysis over the condensed financial statements and concluded that the condensed financial statements are still in accordance with US GAAP.

Changes in Internal Control Over Financial Reporting

~~During~~There ~~the~~was ~~most~~no ~~recently~~change ~~completed~~in our internal control over financial reporting that occurred during the fiscal quarter, ~~there~~of ~~has~~June ~~been~~30, no2021 ~~change~~covered inby ~~our~~this ~~internal~~Quarterly ~~control~~Report ~~over~~on ~~financial~~Form ~~reporting~~10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting, asother ~~the~~than ~~circumstances that led to the restatement of our financial statements~~ described ~~in this Report had not yet been identified~~herein.

~~Our~~Management ~~internal~~has ~~control~~implemented ~~over~~remediation ~~financial~~steps ~~reporting~~to ~~did~~address ~~not result in~~ the ~~proper~~material ~~classification~~weakness ofand ~~our~~to ~~warrants.~~improve ~~Since their issuance on July 16, 2019,~~ our ~~warrants~~internal ~~have~~control ~~been~~over ~~accounted~~financial ~~for as equity within our balance sheet~~reporting. ~~On April 12~~Specifically, ~~2021,~~we ~~the~~enhanced ~~SEC Staff issued~~ the ~~SEC~~supervisory ~~Staff~~review ~~Statement~~of accounting procedures in ~~which~~this ~~the~~financial ~~SEC~~reporting ~~Staff~~area ~~expressed~~and ~~its~~expanded ~~view that certain terms~~ and ~~conditions~~improved ~~common~~our toreview ~~SPAC~~process ~~warrants~~for ~~may~~complex ~~require~~securities ~~the~~and ~~warrants~~related toaccounting ~~be classified as liabilities on the SPAC’s balance sheet as opposed to equity~~standards. ~~After~~As ~~discussion~~of ~~and~~June ~~evaluation~~30, ~~taking into consideration the SEC Staff Statement~~2021, ~~including~~this ~~with~~has ~~our~~not ~~independent~~been ~~auditors,~~fully ~~we have concluded that our warrants should be presented as liabilities with subsequent fair value remeasurement~~remediated.

To remediate this material weakness, we developed a remediation plan with assistance from our accounting advisors and have dedicated significant resources and efforts to the remediation and improvement of our internal control over financial reporting. While we have processes to identify and appropriately apply applicable accounting requirements, we plan to enhance our system of evaluating and implementing the complex accounting standards that apply to our financial statements. Our plans at this time include providing enhanced access to accounting literature, research materials and documents and increased communication among our personnel and third-party professionals with whom we consult regarding complex accounting applications. The elements of our remediation plan can only be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended effects.

Table of Contents

PART II - OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS.

None.

ITEM 1A.

RISK FACTORS.

Factors that could cause our actual results to differ materially from those in this report include the risk factors described in our Annual Report on Form 10-K/A for the year ended December 31, 2020 filed with the SEC on May 26, 2021. As of the date of this Report, there have been no material changes to the risk factors disclosed in our Annual Report filed with the SEC.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS FROM REGISTERED SECURITIES.

On July 16, 2019, we consummated our Initial Public Offering of 17,250,000 Units, inclusive of 2,250,000 Units sold on August 2, 2019 pursuant to the underwriters exercising their over-allotment option. The Units were sold at an offering price of $10.00 per Unit, generating total gross proceeds of $172,500,000. Each Unit consisted of one Class A ordinary share of the Company, par value $0.0001 per share, and one-half of one redeemable warrant of the Company. Credit Suisse acted as the sole book running manager and I-Bankers Securities, Inc. as the co-manager of the offering. The securities sold in the offering were registered under the Securities Act on a registration statement on Form S-1 (No. 333-232240). The SEC declared the registration statement effective on July 11, 2019.

Table of Contents

Simultaneously with the consummation of the Initial Public Offering, we consummated a private placement of 5,000,000 Private Placement Warrants to our Sponsor at a price of $1.00 per Private Placement Warrant, generating total proceeds of $5,000,000. Thereafter, the Company consummated the sale of an additional 450,000 Private Placement Warrants at a price of $1.00 per warrant, generating total proceeds of $450,000. Such securities were issued pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.

The Private Placement Warrants are the same as the warrants underlying the Units sold in the Initial Public Offering, except that Private Placement Warrants are not transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants are exercisable on a cashless basis and are non-redeemable so long as they are held by the initial purchasers or their permitted transferees.

Of the gross proceeds received from the Initial Public Offering, the full exercise of the over-allotment option and the Private Placement Warrants, $172,500,000 was placed in the Trust Account.

We paid a total of $3,450,000 underwriting discounts and commissions and $736,907 for other costs and expenses related to the Initial Public Offering. In addition, the underwriters agreed to defer $6,037,500 in underwriting discounts and commissions.

For a description of the use of the proceeds generated in our Initial Public Offering, see Part I, Item 2 of this Quarterly Report.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4.

MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5.

OTHER INFORMATION.

None.

ITEM 6.

EXHIBITS.

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

No.		Description of Exhibit
31.1*		Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*		Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*		XBRL Instance Document
101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document
101.SCH*		XBRL Taxonomy Extension Schema Document
101.DEF*		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*		XBRL Taxonomy Extension Labels Linkbase Document
101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document

* Filed herewith. ** Furnished herewith.

** Furnished herewith.

Table of Contents

PART III - SIGNATURES

Pursuant to the requirements of Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SC Health Corporation
Date: May 28, 2021		/s/ Angelo John Coloma
Date: August 10, 2021		/s/ Angelo John Coloma
	Name:	Angelo John Coloma
	Title:	Chief Executive Officer
		(Principal Executive Officer)
Date: May 28, 2021		/s/ Eric Teo
Date: August 10, 2021		/s/ Eric Teo
	Name:	Eric Teo
	Title:	Chief Financial Officer
		(Principal Financial and Accounting Officer)

Filing Compare · SC Health Corp